IN THE CLAIMS:

Please amend claims 1, 7, 12 and 33, cancel claims 4, 9-11, 15, 18, 36, 42, 43, 46, 49, 50, 52-54 and 56-58, and add new claim 59-91 as follows.

This listing of claims will replace all prior versions, and listings of the claims in the application.

Listing of the claims

1. (**Currently amended**) A pyrogen-free composition comprising a plasmid comprising a nucleotide sequence that encodes an immunogen operably linked to regulatory elements and a nucleotide sequence that encodes an immunomodulating protein operably linked to regulatory elements, wherein said immunomodulating protein is ~~selected from the group consisting of: L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, MadCAM-1, LFA-1, VLA-1. Mac-1, pl50.95, PECAM, ICAM-2, ICAM-3, CD2, LFA3, mutant forms of IL-18, CD40, CD40L, vascular growth factor, IL-7, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Flt, Apo-l, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4,~~ DR5, ~~KILLER, TRAIL-R2, TRICK2, DR6, and Caspase ICE~~ and wherein said immunogen is a pathogen antigen selected from the group consisting of an influenza antigen, an HIV-1 antigen and an HSV antigen.

2-5. (**Canceled**)

6. (**Previously presented**) An injectable pharmaceutical composition comprising the pyrogen free composition of claim 1.

7. (**Currently amended**) A method of inducing cytotoxic T cell response in an individual against an immunogen comprising administering by intramuscular injection to said individual a ~~pyrogen free~~ composition comprising a plasmid comprising a nucleotide sequence that encodes

an immunogen operably linked to regulatory elements and a nucleotide sequence that encodes an immunomodulating protein operably linked to regulatory elements, wherein said immunomodulating protein ~~is selected from the group consisting of: L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, MadCAM-1, LFA-1, VLA-1. Mac-1, pl50.95, PECAM, ICAM-2, ICAM-3, CD2, LFA3, mutant forms of IL-18, CD40, CD40L, vascular growth factor, IL-7, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Flt, Apo-l, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4,~~ DR5, ~~KILLER, TRAIL-R2, TRICK2, DR6, and Caspase ICE~~ and wherein said immunogen is a pathogen antigen.

8-11. (**Canceled**)

12. (**Currently amended**) A pyrogen-free composition comprising two plasmids: a first plasmid comprising a nucleotide sequence that encodes an immunogen operably linked to regulatory elements; and a second plasmid comprising a nucleotide sequence that encodes an immunomodulating protein operably linked to regulatory elements, wherein said immunomodulating protein is ~~selected from the group consisting of: L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, MadCAM-1, LFA-1, VLA-1. Mac-1, pl50.95, PECAM, ICAM-2, ICAM-3, CD2, LFA3, mutant forms of IL-18, CD40, CD40L, vascular growth factor, IL-7, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Flt, Apo-l, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4,~~ DR5, ~~KILLER, TRAIL-R2, TRICK2, DR6, and Caspase ICE~~ and wherein said immunogen is a pathogen antigen selected from the group consisting of an influenza antigen, an HIV-1 antigen and an HSV antigen.

13–16. (**Canceled**)

17. (**Previously presented**) An injectable pharmaceutical composition comprising the pyrogen free composition of claim 12.

18–32. (**Canceled**)

33. (**Currently amended**) A method of inducing cytotoxic T cell response in an individual against an immunogen comprising administering to said individual by intramuscular injection a composition comprising two plasmids: a first plasmid comprising a nucleotide sequence that encodes said immunogen operable linked to regulatory elements; and a second plasmid ~~nucleic acid molecule~~ comprising a nucleotide sequence that encodes an immunomodulating protein operably linked to regulatory elements, wherein said immunomodulating protein is ~~selected from the group consisting of: L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, MadCAM-1, LFA-1, VLA-1. Mac-1, pl50.95, PECAM, ICAM-2, ICAM-3, CD2, LFA3, mutant forms of IL-18, CD40, CD40L, vascular growth factor, IL-7, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Flt, Apo-l, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4,~~ DR5, ~~KILLER, TRAIL-R2, TRICK2, DR6, and Caspase ICE~~ and wherein the immunogen is a pathogen antigen.

34–54. (**Canceled**)

55. (**Previously presented**) A method of claim 33 wherein said immunogen is a viral antigen.

56–58. (**Canceled**)

59. (**New**) The pyrogen-free composition of claim 1 wherein said immunogen is an influenza antigen.

60. (**New**) An injectable pharmaceutical composition comprising the composition of claim 59.

61. (**New**) The pyrogen-free composition of claim 1 wherein said immunogen is an HIV-1 antigen.

62. (**New**) An injectable pharmaceutical composition comprising the composition of claim 61.

63. (**New**) The pyrogen-free composition of claim 1 wherein said immunogen is an HSV antigen.

64. (**New**) An injectable pharmaceutical composition comprising the composition of claim 63.

65. (**New**) The method of claim 7 wherein said composition is pyrogen free.

66. (**New**) The method of claim 7 wherein said immunogen is a viral antigen.

67. (**New**) The method of claim 66 wherein said composition is pyrogen free.

68. (**New**) The method of claim 7 wherein the immunogen is selected from the group consisting of: an influenza antigen, an HIV-1 antigen and an HSV antigen.

69. (**New**) The method of claim 68 wherein said composition is pyrogen free.

70. (**New**) The method of claim 7 wherein said immunogen is an influenza antigen.

71. (**New**) The method of claim 70 wherein said composition is pyrogen free.

72. (**New**) The method of claim 7 wherein said immunogen is an HIV-1 antigen.

73. (**New**) The method of claim 72 wherein said composition is pyrogen free.

74. (**New**) The method of claim 7 wherein said immunogen is a HSV antigen.

75. (**New**) The method of claim 74 wherein said composition is pyrogen free.

76. (**New**) The pyrogen-free composition of claim 12 wherein said immunogen is an influenza antigen.

77. (**New**) An injectable pharmaceutical composition comprising the composition of claim 76.

78. (**New**) The pyrogen-free composition of claim 12 wherein said immunogen is an HIV-1 antigen.

79. (**New**) An injectable pharmaceutical composition comprising the composition of claim 78.

80. (**New**) The pyrogen-free composition of claim 12 wherein said immunogen is an HSV antigen.

81. (**New**) An injectable pharmaceutical composition comprising the composition of claim 80.

82. (**New**) The method of claim 33 wherein said composition is pyrogen free.

83. (**New**) The method of claim 55 wherein said composition is pyrogen free.

84. (**New**) The method of claim 33 wherein the immunogen is selected from the group consisting of: an influenza antigen, an HIV-1 antigen and an HSV antigen.

85. (**New**) The method of claim 86 wherein said composition is pyrogen free.

86. (**New**) The method of claim 86 wherein said immunogen is an influenza antigen.

87. (**New**) The method of claim 88 wherein said composition is pyrogen free.

88. (**New**) The method of claim 86 wherein said immunogen is an HIV-1 antigen.

89. (**New**) The method of claim 90 wherein said composition is pyrogen free.

90. (**New**) The method of claim 86 wherein said immunogen is a HSV antigen.

91. (**New**) The method of claim 90 wherein said composition is pyrogen free.